Seattle, WA | July 2, 2012

The Infectious Disease Research Institute (IDRI) continues to expand its Board of Directors, comprised of international leaders in industry and academia, with the recent addition of Massimo Radaelli, Ph.D., who has 25 years of progressive experience in the biotech and pharmaceutical industries.

Dr. Radaelli is Chairman, President & CEO of Noventia Pharma, a company he founded in 2009. Noventia Pharma operates in Southern Europe, and offers a product portfolio of pharmaceuticals with a specialized business dedicated to treatments of rare and neglected diseases. Dr. Radaelli also serves as Executive Chairman of Bioakos Pharma, a specialty pharmaceutical company based in Florence, Italy, and focused in the areas of dermatology, gynecology and pediatrics. Prior to founding Noventia Pharma, Dr. Radaelli served as President and Chief Executive Officer of Dompe International SA, where he was responsible for the company’s global sales and export activities. Dr. Radaelli received a degree in pharmaceutical sciences and a Ph.D. in clinical pharmacology from the University of Milan and an Executive Master of Business degree from Bocconi University of Milan.

“Massimo’s wealth of knowledge in the international biotech and pharmaceutical industries makes him a terrific addition to IDRI’s board, said Stewart Parker, CEO of IDRI. With our focus on developing products to solve global health challenges caused by infectious diseases, IDRI will benefit from Massimo’s extensive experience in developing key industry partnerships and launching products worldwide.”

In addition to being a member of IDRI’s Board of Directors, Dr. Radaelli serves on a number of corporate boards in Europe and in US, including Massachusetts-based ARIAD Pharmaceuticals, Inc., which is developing breakthrough medicines for cancer patients with difficult-to-treat malignancies, such as chronic myeloid leukemia and non-small cell lung cancer.

Contacts:

IDRI: Lee Schoentrup | 206.518.6290 | media@idri.org